查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863424

神經系統疾病影像模式及軟體市場（依影像模式、軟體類型、疾病適應症、最終用戶、實施類型及通路分類）－2025-2032年全球預測

Brain Disease Modalities & Software Market by Imaging Modality, Software Type, Disease Indication, End User, Deployment Mode, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，腦部疾病治療設備和軟體市場將成長至 244.4 億美元，複合年成長率為 5.34%。

關鍵市場統計數據
基準年 2024 161.1億美元
預計年份：2025年 169.8億美元
預測年份 2032 244.4億美元
複合年成長率 (%) 5.34%

影像創新、智慧軟體和臨床需求的綜合視角正在重塑腦部疾病的診斷和治療。

先進影像技術、智慧軟體和不斷發展的臨床路徑的融合正在重塑腦部疾病的檢測、監測和管理方式。本執行摘要總結了影響神經系統疾病診斷和決策支持生態系統的關鍵變革因素，並將技術創新與不斷變化的臨床需求和監管要求聯繫起來。包括醫療設備製造商、軟體開發商、臨床網路和研究機構相關人員，都在尋求一個互通性、數據可靠性和演算法透明度與診斷靈敏度同等重要的環境。

臨床上對能夠在診療現場提供可操作見解且可擴展至各種醫療環境的工具的需求日益成長。同時，人工智慧和深度學習架構的普及對輔助臨床醫生的軟體提出了新的性能標準和設計要求。因此，各機構必須權衡提高診斷準確性的潛力與實施、資料管治和長期臨床檢驗等實際操作因素。

本引言概述了技術基礎、推動採用的相關人員動態以及對產品藍圖產生重大影響的監管和報銷環境，為後續分析提供了一個框架，旨在為尋求將投資決策與臨床價值、實施可行性和永續競爭優勢相結合的經營團隊提供清晰的分析觀點。

多模態成像、演算法智慧和分散式醫療服務技術的整合正在重新定義臨床價值和競爭優勢。

隨著計算方法的成熟、影像能力的多樣化以及醫療服務分散化，腦疾病診斷和軟體領域正經歷變革性的轉變。在所有成像模式下，高解析度採集、多模態融合和先進的後處理技術的結合，使得以往隱性生物標記能夠在常規工作流程中進行測量。電診斷和功能測試技術正透過改進的攜帶式平台和訊號處理技術進行革新，而混合成像方法則能夠更精確地對神經退化性疾病疾病和急性神經系統疾病進行表現型分析。

軟體進步同樣具有革命性意義。將深度學習和機器學習技術整合到臨床決策支援和診斷軟體中，拓展了自動解讀、病灶檢測和預後建模的範圍。這些演算法系統擴大使用多機構資料檢驗，並朝著要求可解釋性和可重複性的監管核准框架邁進。工作流程管理和遠端醫療平台正在彌合影像中心、診所和三級醫院之間的鴻溝，從而實現遠端閱片、即時監測和協作式醫療模式。

同時，其他結構性因素也在加速變革。對人工智慧醫療設備的監管審查日益嚴格、雲端和混合部署架構的興起，以及對標準化資料交換的需求，都在推動產品架構的重構。隨著醫療服務提供者尋求最佳化患者吞吐量，臨床醫生要求使用更直覺的介面，供應商必須優先考慮能夠滿足不同終端用戶環境需求的模組化解決方案，同時保持強大的資料管治。這些變化正在重新定義競爭優勢，使其從孤立的產品功能轉向生態系統互通性和持續的臨床證據產生。

分析2025年關稅調整如何重塑神經診斷硬體和軟體生態系統的籌資策略、供應鏈韌性和實施方案。

2025年關稅政策的變化為神經技術領域的全球供應鏈、籌資策略和跨境服務交付帶來了新的考量。針對特定醫療設備類別和軟體相關硬體組件的關稅促使製造商和經銷商重新評估籌資策略，他們正在考慮近岸外包、組件替代和合約保障措施，以降低成本波動。其影響不僅限於資本設備，也延伸至相關的服務模式，分級關稅影響企業在本地部署設備和雲端服務之間的選擇。

為因應這項挑戰，各機構正在加速供應鏈細分，以維持關鍵功能，同時降低關稅帶來的價格波動風險。供應商和醫療機構為確保臨床服務的連續性，普遍採取了合約重新談判、更保守的庫存策略以及有選擇地進行供應商多元化等措施。對於捆綁硬體相關解決方案的軟體供應商而言，關稅促使他們重新評估授權結構，更加重視訂閱模式和雲端原生模式，以將最終用戶成本與硬體採購週期脫鉤。

此外，關稅壓力凸顯了自適應部署模式的價值，例如混合解決方案，該方案可在本地進行敏感資料處理，同時利用雲端服務進行非敏感分析和更新。跨多個司法管轄區的醫療系統目前已將關稅因素納入其採購框架，並與臨床績效標準和監管合規性並列。在地緣政治和經濟因素可能迅速改變成本結構的環境下，納入貿易政策情境的彈性規劃對於維持產品部署和維持利潤率至關重要。

深度分割觀點將影像方式、軟體類型、疾病適應症、終端用戶環境、實施類型和通路連結起來，以輔助產品策略規劃。

了解市場區隔對於確定產品開發優先順序、最佳化商業化策略以及使臨床檢驗活動與最終用戶需求保持一致至關重要。影像學診斷路徑包括：電腦斷層掃描（CT），包括常規CT和頻譜CT；腦電圖（EEG），分為攜帶式和常規腦電圖；磁振造影（MRI），包括擴散張量成像（DTI）、功能性磁振造影（fM RI）和結構磁振造影；磁振造影（MEG），分為誘發電位和靜息態兩種方法；正子斷層掃描（PET），包括澱粉樣蛋白和FDG示蹤劑；以及從高解析度成像到經顱都卜勒超音波的各種超音波方法。每種成像方式都有其獨特的資料特徵、臨床工作流程和整合挑戰，這些都會影響軟體的設計和實施。

在軟體方面，分割技術涵蓋了基於人工智慧的解決方案（利用深度學習和機器學習演算法）、臨床決策支援平台、診斷軟體（例如影像分析和分割工具）、監測軟體（包括神經生理監測和遠端患者監護）、遠距遠端醫療平台以及工作流程管理解決方案。旨在實現自主解讀的演算法組件和支援臨床醫生決策的軟體具有截然不同的技術架構和檢驗路徑，需要特定的證據基礎和互通性標準。

疾病適應症細分涵蓋了廣泛的神經系統疾病，包括阿茲海默症、局部和整體癲癇、多發性硬化症、帕金森氏症、中風（包括出血性和缺血性頻譜）以及輕度和重度創傷性腦損傷。患者診療路徑、生物標記相關性以及急性期和長期監測的平衡決定了這些適應症的診斷優先順序。最終用戶細分涵蓋了門診手術中心、神經內科和復健專科診所、影像診斷中心、公立和私立醫院以及轉化科學研究機構。部署模式包括雲端基礎、混合和本地部署架構，每種架構在延遲、資料主權和維護成本方面各有優劣。分銷管道涵蓋了從直銷到分銷商和線上平台，這會影響產品上市時間、售後服務模式和合作夥伴賦能策略。整合這些細分層對於設計產品藍圖至關重要，該路線圖需能夠滿足不同醫療環境中的臨床工作流程、監管要求和商業性動態。

區域動態正在影響美洲、歐洲、中東和非洲以及亞太地區的採用和商業化趨勢，而這些趨勢又受到監管、基礎設施和支付方多樣性的驅動。

區域特徵對技術採納路徑、監管預期和夥伴關係模式持續產生顯著影響。在美洲，醫療服務體系強調檢驗診斷技術的快速實用化，其特點是商業導向的報銷框架鼓勵早期應用，尤其是在先進的醫院系統和專科診所。該地區完善的研究基礎設施支持臨床合作和多中心檢驗研究，這些研究成果通常用於廣泛的監管申報和商業化宣傳活動。

歐洲、中東和非洲地區（EMEA）是一個多元化的環境，監管協調的努力與各國層面的顯著差異並存。歐洲嚴格的法規和資料保護標準促使供應商優先考慮演算法透明度和可靠的臨床證據。同時，鑑於集中式影像基礎設施有限，中東和北非地區（MENA）市場對雲端服務的需求呈指數級成長。在幅員遼闊的亞太地區（APAC），可近性、成本壓力和多樣化的支付模式正在推動雲端服務的廣泛應用，這需要靈活的定價策略和部署方案。

亞太地區的特點是基礎設施快速擴張、政府主導投資醫療現代化以及充滿活力的區域創新生態系統。由於支付方結構多樣且臨床專業水平參差不齊，供應商採取了雙管齊下的策略：一方面為擁有先進數位基礎設施的都市區提供擴充性的雲端基礎解決方案，另一方面為網路連接有限的地區提供穩健的本地部署或混合系統。與區域研究機構建立合作關係以及進行在地化的檢驗研究，對於成功進入亞太市場並獲得市場認可至關重要。

策略性企業行動和夥伴關係模式推動神經診斷和軟體供應商的技術差異化、臨床檢驗和可擴展商業化。

在腦疾病診斷和軟體領域，主要企業正透過互補策略實現差異化，這些策略融合了技術創新、臨床證據生成和夥伴關係生態系統。許多成熟的醫療設備製造商正在擴展其影像診斷平台，整合嵌入式分析功能並增強連接性；而專業軟體公司則專注於可擴展的人工智慧流程和雲端原生服務，優先考慮互通性和監管合規性。新興技術提供者（通常源自學術研究）則憑藉新型生物標記、訊號處理技術的進步或旨在加速臨床工作流程的改進型使用者介面展開競爭。

硬體供應商和軟體開發商之間的策略聯盟和授權合約已成為加速臨床應用和擴大分銷管道的關鍵。此外，與臨床網路和研究機構的夥伴關係也日益受到重視，以確保真實世界檢驗並應對複雜的報銷流程。各公司也正在投資上市後監測和持續學習系統，以確保演算法在不同患者群體和影像平台上的表現保持穩定。

在營運方面，成功的企業優先考慮模組化產品架構，這些架構可以部署在本地、混合配置或透過雲端服務部署，以滿足醫院、診所和診斷中心的多樣化需求。商業性成功的基礎在於完善的支援模式、專業服務以及能夠減輕臨床醫生在採用過程中負擔的培訓計劃。這些策略選擇體現了產業致力於在創新與擴充性、合規性和臨床接受度之間取得平衡的承諾。

為供應商提供切實可行的策略重點和實施步驟，以加速產品應用、確保合規性，並在各種醫療保健環境中提供可衡量的臨床價值。

在不斷變化的環境中，希望創造價值的領導者必須協調技術、臨床檢驗、監管準備和商業性執行等方面的策略。首先，應優先考慮產品設計的互通性和模組化，以便於整合到不同的醫院和診所基礎設施中，從而實現快速普及並降低最終用戶的整體擁有成本。同時，應投資於清晰的演算法管治框架，以支援可解釋性、偏差緩解和生命週期管理，從而滿足日益嚴格的監管要求並建立臨床醫生的信任。

第二，將臨床證據生成納入商業化藍圖，儘早與治療中心和研究機構合作，以獲得可重複的、經過同儕審查的結果。這些合作應超越回顧性檢驗，進行前瞻性、真實世界研究，以證明臨床效用和工作流程效率。第三，採用靈活的部署策略，支援雲端、混合和本地部署配置，以應對資料主權、延遲和連接性方面的限制。這種靈活性對於應對受價格主導的採購趨勢和特定地區的基礎設施限制至關重要。

第四，透過制定針對終端用戶群的分銷和定價模式，最佳化您的市場推廣策略。雖然直接參與對於大型醫院和醫療保健系統至關重要，但經銷商和線上管道對於加速產品滲透到診斷中心和門診網路也十分有效。最後，建立健全的支援體系，包括培訓、維護和結果追蹤服務，以維持產品應用、收集上市後數據並建立永續的競爭優勢。實施這些建議需要跨部門合作，並將可衡量的臨床結果作為衡量成功的關鍵指標。

我們採用穩健的混合方法研究方法，結合專家的初步研究、二手證據綜合和檢驗，以支持可操作和可靠的研究結果。

本報告的分析是基於一套綜合調查方法，該方法結合了初步研究、嚴謹的二手資訊收集以及多種調查方法的三角驗證，以確保分析的可靠性。初步研究包括對臨床負責人、技術架構師、採購專業人員和監管顧問進行結構化訪談，以收集關於技術採納促進因素、實施挑戰和證據要求的第一手見解。這些專家的見解為臨床工作流程、資料互通性限制和實際效能預期提供了細緻的背景資訊。

二次研究整合了同行評審文獻、技術白皮書、監管指導文件和臨床實踐建議，以建立專業知識基礎並檢驗技術主張。在適當情況下，參考了公共臨床註冊庫和標準機構的出版物，以確保與當前的臨床和技術規範保持一致。質性研究結果輔以技術特性、實施模式和檢驗方法的結構化比較評估，以清楚地展示每類解決方案的相對優點和限制。

方法論三角驗證確保了資料的完整性，透過交叉檢驗相關人員的證詞與已發表的證據和監管文件，確保了資料的準確性。研究過程強調假設設定的透明度、資料來源的嚴格揭露，以及在專家意見不一致時採用共識建構方法。在整個原始資料收集過程中，始終遵循倫理考量和資料隱私保護原則。最終的研究結果將整合起來，為行業領導者和醫療保健提供者的實際決策提供支援。

摘要強調，技術成熟度、臨床證據和適應性商業化將決定長期的臨床影響和應用路徑。

我們對技術趨勢、監管變化和區域動態的綜合分析表明，未來診斷準確性和臨床決策支援將越來越依賴營運適應性和可證實的臨床價值。影像技術和演算法系統正從概念概念驗證階段發展成為可實際應用的工具，只要它們具備嚴格的檢驗、可解釋的性能特徵以及針對區域限制量身定做的部署模式，就能影響診療路徑。價格政策、不斷變化的監管規定以及支付方期望的累積效應凸顯了製定穩健的商業策略和適應性強的產品架構的必要性。

醫療服務提供者面臨的挑戰在於，如何採用能夠與現有工作流程無縫整合，同時又能實際提升診斷信心和效率的解決方案。對於供應商而言，成功的關鍵在於平衡創新與嚴謹的臨床證據生成，確保互通性，並提供全面的支持，以促進不同終端使用者環境下的解決方案應用。最終，技術、證據和執行三者之間的相互作用將決定哪些解決方案能夠產生永續的臨床影響並獲得市場認可。積極應對這些挑戰的相關人員將更有利於改善患者預後，並實現其長期策略目標。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 擴展雲端基礎的神經影像分析平台，以整合多模態MRI和PET數據，從而獲得即時診斷資訊。
  • 透過將穿戴式生物感測器與人工智慧平台結合，對帕金森氏症患者的運動波動進行持續監測
  • 推出一款遠距神經病學軟體解決方案，可實現遠端腦電圖監測和中風復健虛擬會診。
  • 多發性硬化症治療中用於個人化治療方案製定的多重生物標記檢測技術的進展
  • 區塊鏈賦能的腦健康資料管理系統的出現，確保了研究機構之間的安全互通性
  • 訂閱式SaaS神經診斷工具的成長：為早期阿茲海默症風險評估提供預測分析
  • 監管部門的核准加速了人工智慧驅動的PET影像分析軟體的商業化，該軟體可用於對腦腫瘤病變進行定量分析。
  • 開發整合雲端遙測技術的虛擬實境認知復健程序，以實現中風復健通訊協定的個人化。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依診斷影像方法分類的腦部疾病模式和軟體市場

  • 電腦斷層掃描
    • 常規CT
    • 頻譜CT
  • 腦電圖（EEG）
    • 攜帶式腦電圖
    • 常規腦電圖
  • 磁振造影
    • 擴散張量造影
    • 功能性磁振造影
    • 結構磁振造影
  • 腦磁圖
    • 引發的反應
    • 靜止狀態
  • 正子斷層掃描
    • 澱粉樣蛋白PET
    • FDG PET
  • 超音波
    • 高解析度
    • 經顱都卜勒

9. 依軟體類型分類的腦部疾病治療模式與軟體市場

  • 基於人工智慧的軟體
    • 深度學習演算法
    • 機器學習演算法
  • 臨床決策支援軟體
  • 診斷軟體
    • 影像分析軟體
    • 分割軟體
  • 監控軟體
    • 神經生理監測
    • 遠端患者監護
  • 遠端醫療平台
  • 工作流程管理軟體

第10章 依疾病指徵分類的腦部疾病治療模式與軟體市場

  • 阿茲海默症
  • 癲癇
    • 局部性發作
    • 整體癲癇發作
  • 多發性硬化症
  • 帕金森氏症
  • 中風
    • 出血性中風
    • 缺血性中風
  • 創傷性腦損傷
    • 輕度創傷性腦損傷
    • 嚴重創傷性腦損傷

第11章 腦疾病治療模式及最終用戶軟體市場

  • 門診手術中心
  • 診所
    • 神經內科診所
    • 復健診所
  • 診斷影像中心
  • 醫院
    • 私立醫院
    • 公立醫院
  • 研究所

12. 依部署模式分類的腦部疾病治療模式與軟體市場

  • 雲端基礎的
  • 混合
  • 本地部署

第13章 腦部疾病治療模式及軟體市場（依分銷管道分類）

  • 直銷
  • 經銷商
  • 線上平台

14. 各地區腦部疾病治療模式及軟體市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 腦疾病治療模式及軟體市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國腦部疾病治療模式及軟體市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Siemens Healthineers AG
    • GE HealthCare Technologies Inc.
    • Koninklijke Philips NV
    • Canon Medical Systems Corporation
    • Hitachi, Ltd.
    • Brainlab AG
    • Elekta AB（publ）
    • Medtronic plc
    • Stryker Corporation
    • IBM Corporation
Product Code: MRR-5C6F41F5AF8F

The Brain Disease Modalities & Software Market is projected to grow by USD 24.44 billion at a CAGR of 5.34% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 16.11 billion
Estimated Year [2025] USD 16.98 billion
Forecast Year [2032] USD 24.44 billion
CAGR (%) 5.34%

Comprehensive orientation to the intersection of imaging innovation, intelligent software, and clinical imperatives reshaping diagnosis and management of brain disorders

The convergence of advanced imaging modalities, intelligent software, and evolving clinical pathways is reshaping how brain diseases are detected, monitored, and managed. This executive summary synthesizes the critical vectors of change affecting diagnostic and decision-support ecosystems for neurological conditions, integrating technological innovation with shifting clinical needs and regulatory scrutiny. Stakeholders across device manufacturers, software developers, clinical networks, and research institutions are navigating an environment where interoperability, data fidelity, and algorithmic transparency are as consequential as diagnostic sensitivity.

Clinical demand is increasingly focused on tools that deliver actionable insights at the point of care and that scale across diverse care settings. Simultaneously, the proliferation of artificial intelligence and deep learning architectures has introduced new performance thresholds and design imperatives for software intended to support clinicians. As a result, organizations must reconcile the promise of higher diagnostic confidence with the operational realities of deployment, data governance, and long-term clinical validation.

This introduction frames the subsequent analysis by outlining the technological building blocks, the stakeholder dynamics that drive adoption, and the regulatory and reimbursement contexts that now exert significant influence over product roadmaps. The aim is to provide a clear analytic lens for executives seeking to align investment decisions with clinical value, implementation feasibility, and sustainable competitive positioning.

How converging advances in multimodal imaging, algorithmic intelligence, and decentralized care delivery are redefining clinical value and competitive differentiation

The landscape for brain disease diagnostics and software is undergoing transformative shifts as computational methods mature, imaging capabilities diversify, and care delivery decentralizes. Across imaging modalities, the combination of higher-resolution acquisition, multimodal fusion, and advanced post-processing has made previously latent biomarkers measurable in routine workflows. Electrodiagnostic and functional techniques are being reimagined through ambulatory platforms and improved signal processing, while hybrid imaging approaches enable more precise phenotyping of neurodegenerative and acute neurological conditions.

Software advances have been equally disruptive. The integration of deep learning and machine learning techniques into clinical decision support and diagnostic software has expanded the scope of automated interpretation, lesion detection, and prognosis modeling. These algorithmic systems are increasingly validated against multi-institutional datasets and are moving toward regulatory acceptance frameworks that demand explainability and reproducibility. Workflow management and telehealth platforms are bridging gaps between imaging centers, clinics, and tertiary care hospitals, enabling remote interpretation, real-time monitoring, and collaborative care models.

Concurrently, other structural forces are accelerating change: tighter regulatory scrutiny around AI-based medical devices, the emergence of cloud and hybrid deployment architectures, and the demand for standardized data exchange are all reshaping product architectures. As providers seek to optimize patient throughput and clinicians demand more intuitive interfaces, vendors must prioritize modular solutions that align with diverse end-user environments while maintaining robust data governance. Taken together, these shifts are redefining competitive differentiation from siloed product features toward ecosystem interoperability and sustained clinical evidence generation.

Analyzing how 2025 tariff adjustments reshaped procurement strategies, supply chain resilience, and deployment choices across neurodiagnostic hardware and software ecosystems

Tariff policy changes in 2025 introduced new considerations for global supply chains, procurement strategies, and cross-border service delivery within the neurotechnology landscape. Tariffs aimed at certain classes of medical equipment and software-related hardware components have driven a reassessment of sourcing strategies, with manufacturers and distributors examining nearshoring, component substitution, and contractual safeguards to mitigate cost volatility. The impact extends beyond capital equipment to associated service models, as tiered duties influence deployment choices between on-premise appliances and cloud-enabled services.

In response, organizations have accelerated supply chain segmentation to preserve critical capabilities while limiting exposure to tariff-driven price shifts. Contract renegotiations, more conservative inventory strategies, and selective supplier diversification have become commonplace as vendor and provider organizations seek to maintain continuity of clinical services. For software providers that bundle hardware-dependent solutions, tariffs have prompted a re-evaluation of licensing structures and greater emphasis on subscription and cloud-native models that decouple end-user costs from hardware procurement cycles.

Moreover, tariff-induced pressures have highlighted the value of adaptable deployment modes, including hybrid solutions that allow sensitive data processing to occur locally while leveraging cloud services for non-sensitive analytics and updates. For health systems operating across jurisdictions, tariff considerations are now embedded in procurement frameworks alongside clinical performance criteria and regulatory compliance. Looking ahead, resilience planning that incorporates trade policy scenarios will be essential for sustaining product rollouts and preserving margins in a landscape where geopolitical and economic levers can rapidly alter cost equations.

Deep segmentation perspective that connects imaging modalities, software types, disease indications, end-user environments, deployment modes, and distribution pathways to inform product strategy

Understanding segmentation is essential for framing product development priorities, tailoring commercialization approaches, and aligning clinical validation efforts with end-user needs. In imaging modalities, diagnostic pathways encompass computed tomography with its conventional and spectral variants, electroencephalography differentiated into ambulatory and routine formats, magnetic resonance imaging that includes diffusion tensor imaging, functional MRI, and structural MRI, magnetoencephalography split into evoked response and resting-state methods, positron emission tomography characterized by amyloid and FDG tracers, and ultrasound approaches ranging from high-resolution imaging to transcranial Doppler assessments. Each modality presents distinct data characteristics, clinical workflows, and integration challenges that influence software design and deployment.

On the software side, segmentation spans AI-based solutions that leverage deep learning and machine learning algorithms, clinical decision support platforms, diagnostic software such as image analysis and segmentation tools, monitoring software divided into neurophysiological monitoring and remote patient monitoring, telehealth platforms, and workflow management solutions. The technical architecture and validation pathways differ markedly between algorithmic components intended for autonomous interpretation and software that augments clinician decision-making, demanding tailored evidence dossiers and interoperability standards.

Disease indication segmentation covers a spectrum of neurological disorders including Alzheimer's disease, epilepsy with focal onset and generalized onset subtypes, multiple sclerosis, Parkinson's disease, stroke encompassing hemorrhagic and ischemic presentations, and traumatic brain injury with mild and severe classifications. Patient pathways, biomarker relevance, and the balance between acute versus longitudinal monitoring shape diagnostic priorities across these indications. End-user segmentation stretches across ambulatory surgical centers, clinics with neurology and rehabilitation subtypes, diagnostic imaging centers, hospitals with private and public distinctions, and research institutes engaged in translational science. Deployment modes include cloud-based, hybrid, and on-premise architectures, each presenting different trade-offs in latency, data sovereignty, and maintenance overhead. Distribution channels run from direct sales to distributors and online platforms, influencing go-to-market cadence, after-sales support models, and partner enablement strategies. Integrating these layers of segmentation is critical for designing product roadmaps that respond to clinical workflows, regulatory requirements, and the commercial dynamics of diverse healthcare settings.

Regional dynamics shaping adoption and commercialization across the Americas, Europe Middle East & Africa, and Asia-Pacific driven by regulation, infrastructure, and payer diversity

Regional dynamics continue to exert a pronounced influence on adoption pathways, regulatory expectations, and partnership models. In the Americas, healthcare delivery structures emphasize rapid translation of validated diagnostics and commercially oriented reimbursement frameworks that facilitate early adoption, particularly within advanced hospital systems and specialist clinics. The region's sizable research infrastructure also supports clinical collaborations and multicenter validation studies that are frequently leveraged for broader regulatory submissions and commercialization campaigns.

Europe, the Middle East & Africa present a heterogeneous environment where regulatory harmonization efforts coexist with significant national-level variation. European regulatory rigor and data protection norms have incentivized vendors to prioritize algorithmic transparency and robust clinical evidence, while markets in the Middle East and Africa exhibit opportunities for leapfrogging to cloud-enabled services in contexts where centralized imaging infrastructure is limited. Accessibility, cost-containment pressures, and diverse payer models necessitate adaptable pricing strategies and flexible deployment options to achieve broader adoption across this expansive region.

The Asia-Pacific region is characterized by rapid infrastructure expansion, strong government-led investments in healthcare modernization, and vibrant local innovation ecosystems. Diverse payer structures and varying levels of clinical specialization drive a dual approach from vendors: offering scalable cloud-based solutions for urban centers with advanced digital infrastructure while providing resilient on-premise or hybrid systems for facilities with constrained connectivity. Collaboration with regional research institutes and localization of validation studies often underpin successful market entry and uptake across Asia-Pacific markets.

Strategic company behaviors and partnership models driving technological differentiation, clinical validation, and scalable commercialization across neurodiagnostic and software vendors

Key companies operating within the brain disease modalities and software space are differentiating through complementary strategies that combine technological innovation, clinical evidence generation, and partnership ecosystems. Many established medical device manufacturers are augmenting imaging platforms with embedded analytics and enhanced connectivity, while specialized software firms focus on scalable AI pipelines and cloud-native services that prioritize interoperability and regulatory readiness. Emerging technology providers, frequently spun out from academic research, are competing on novel biomarkers, signal processing advances, or improved user interfaces designed to accelerate clinical workflows.

Strategic collaborations and licensing agreements between hardware vendors and software developers have become central to accelerating time-to-clinic and expanding distribution reach. Additionally, partnerships with clinical networks and research institutes are increasingly used to secure real-world validation and to navigate complex reimbursement pathways. Companies are also investing in post-market surveillance and continuous learning systems to ensure algorithmic performance remains robust across diverse patient populations and imaging platforms.

Operationally, successful organizations emphasize modular product architectures that can be deployed on-premise, in hybrid configurations, or via cloud services, thereby accommodating the heterogeneous needs of hospitals, clinics, and diagnostic centers. Commercial excellence is underpinned by comprehensive support models, professional services for implementation, and training programs that reduce clinician friction during adoption. Collectively, these strategic choices reflect an industry that is balancing innovation with pragmatic approaches to scale, compliance, and clinical acceptance.

Practical strategic priorities and implementation steps for vendors to accelerate adoption, ensure compliance, and deliver measurable clinical value across diverse care settings

Leaders seeking to capture value in this evolving landscape should align their strategies across technology, clinical validation, regulatory preparedness, and commercial execution. First, prioritize interoperability and modularity in product design to facilitate integration into heterogeneous hospital and clinic infrastructures, enabling faster deployments and lower total cost of ownership for end users. Concurrently, invest in clear algorithmic governance frameworks that support explainability, bias mitigation, and lifecycle management to meet increasingly stringent regulatory expectations and to build clinician trust.

Second, embed clinical evidence generation into commercialization roadmaps by forging early partnerships with treatment centers and research institutes to produce reproducible, peer-reviewed outcomes. These collaborations should extend beyond retrospective validation into prospective, real-world studies that demonstrate clinical utility and workflow efficiency. Third, adopt flexible deployment strategies that permit cloud, hybrid, and on-premise configurations to address data sovereignty, latency, and connectivity constraints; this flexibility will be crucial when navigating tariff-driven procurement dynamics or region-specific infrastructure limitations.

Fourth, refine go-to-market approaches by tailoring distribution and pricing models to end-user segmentation. Direct engagement is often essential for large hospitals and health systems, whereas distributors and online channels can accelerate penetration within diagnostic centers and ambulatory networks. Finally, build a robust post-deployment support ecosystem that includes training, maintenance, and outcome-tracking services to sustain utilization, gather post-market data, and create defensible competitive advantage over time. Executing on these recommendations will require cross-functional alignment and an emphasis on measurable clinical outcomes as the primary metric of success.

Robust mixed-methods research approach combining primary expert engagements, secondary evidence synthesis, and triangulated validation to underpin practical, trustworthy insights

The analysis underpinning this report draws on an integrated research methodology that combines primary engagements, rigorous secondary intelligence, and methodological triangulation to ensure analytical robustness. Primary research included structured interviews with clinical leaders, technical architects, procurement specialists, and regulatory advisors to capture firsthand perspectives on adoption drivers, implementation challenges, and evidence requirements. These expert inputs offered nuanced context on clinical workflows, data interoperability constraints, and real-world performance expectations.

Secondary research synthesized peer-reviewed literature, technology whitepapers, regulatory guidance documents, and clinical practice recommendations to establish a foundation of domain knowledge and to validate technical assertions. Where applicable, public clinical registries and standards bodies' publications were referenced to ensure alignment with prevailing clinical and technical norms. Qualitative insights were complemented by structured comparative assessments of technology features, deployment modes, and validation practices to articulate relative strengths and limitations across solution classes.

Data integrity was maintained through methodological triangulation, cross-checking stakeholder testimonies against published evidence and regulatory documents. The research process emphasized transparency in assumption-setting, careful delineation of data sources, and the use of consensus approaches when reconciling divergent expert views. Ethical considerations and data privacy compliance were observed throughout primary data collection, and findings were synthesized to support practical decision-making for industry leaders and healthcare providers.

Concluding synthesis highlighting how technology maturity, clinical evidence, and adaptive commercialization will determine long-term clinical impact and adoption trajectories

The synthesis of technological trends, regulatory shifts, and regional dynamics points to a future in which diagnostic precision and clinical decision support are increasingly interwoven with operational adaptability and demonstrable clinical value. Imaging modalities and algorithmic systems are moving beyond proof-of-concept to operationalized tools that can influence care pathways, provided they are accompanied by rigorous validation, explainable performance characteristics, and deployment models attuned to local constraints. The cumulative effects of tariff policies, regulatory evolution, and payer expectations underscore the need for resilient commercial strategies and adaptable product architectures.

For healthcare providers, the imperative is to adopt solutions that integrate seamlessly with existing workflows while offering tangible improvements in diagnostic confidence and efficiency. For vendors, success will hinge on balancing innovation with disciplined clinical evidence generation, interoperability commitments, and comprehensive support structures that facilitate adoption across varied end-user environments. Ultimately, the interplay of technology, evidence, and execution will determine which solutions achieve sustainable clinical impact and market acceptance. Stakeholders who proactively address these dimensions will be best positioned to advance patient outcomes and to realize long-term strategic objectives.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of cloud-based neuroimaging analytics platforms integrating multimodal MRI and PET data for real-time diagnostic insights
  • 5.2. Integration of wearable biosensors with AI-powered platforms to monitor Parkinson's disease motor fluctuations continuously
  • 5.3. Deployment of tele-neurology software solutions enabling remote EEG monitoring and virtual consultations for stroke rehabilitation
  • 5.4. Advancements in multiplexed biomarker assays for personalized treatment planning in multiple sclerosis therapies
  • 5.5. Emergence of blockchain-enabled brain health data management systems ensuring secure interoperability among research centers
  • 5.6. Growth of subscription-based SaaS neurodiagnostic tools offering predictive analytics for early Alzheimer's disease risk assessment
  • 5.7. Regulatory approvals accelerating commercialization of AI-driven PET imaging software for quantitative oncological brain lesion analysis
  • 5.8. Development of VR-based cognitive rehabilitation programs integrated with cloud telemetry to personalize stroke recovery protocols

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Brain Disease Modalities & Software Market, by Imaging Modality

  • 8.1. Computed Tomography
    • 8.1.1. Conventional Ct
    • 8.1.2. Spectral Ct
  • 8.2. Electroencephalography
    • 8.2.1. Ambulatory Eeg
    • 8.2.2. Routine Eeg
  • 8.3. Magnetic Resonance Imaging
    • 8.3.1. Diffusion Tensor Imaging
    • 8.3.2. Functional Mri
    • 8.3.3. Structural Mri
  • 8.4. Magnetoencephalography
    • 8.4.1. Evoked Response
    • 8.4.2. Resting State
  • 8.5. Positron Emission Tomography
    • 8.5.1. Amyloid Pet
    • 8.5.2. Fdg Pet
  • 8.6. Ultrasound
    • 8.6.1. High Resolution
    • 8.6.2. Transcranial Doppler

9. Brain Disease Modalities & Software Market, by Software Type

  • 9.1. Ai Based Software
    • 9.1.1. Deep Learning Algorithms
    • 9.1.2. Machine Learning Algorithms
  • 9.2. Clinical Decision Support Software
  • 9.3. Diagnostic Software
    • 9.3.1. Image Analysis Software
    • 9.3.2. Segmentation Software
  • 9.4. Monitoring Software
    • 9.4.1. Neurophysiological Monitoring
    • 9.4.2. Remote Patient Monitoring
  • 9.5. Telehealth Platform
  • 9.6. Workflow Management Software

10. Brain Disease Modalities & Software Market, by Disease Indication

  • 10.1. Alzheimer's Disease
  • 10.2. Epilepsy
    • 10.2.1. Focal Onset
    • 10.2.2. Generalized Onset
  • 10.3. Multiple Sclerosis
  • 10.4. Parkinson's Disease
  • 10.5. Stroke
    • 10.5.1. Hemorrhagic Stroke
    • 10.5.2. Ischemic Stroke
  • 10.6. Traumatic Brain Injury
    • 10.6.1. Mild Tbi
    • 10.6.2. Severe Tbi

11. Brain Disease Modalities & Software Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Clinics
    • 11.2.1. Neurology Clinics
    • 11.2.2. Rehabilitation Clinics
  • 11.3. Diagnostic Imaging Centers
  • 11.4. Hospitals
    • 11.4.1. Private Hospitals
    • 11.4.2. Public Hospitals
  • 11.5. Research Institutes

12. Brain Disease Modalities & Software Market, by Deployment Mode

  • 12.1. Cloud Based
  • 12.2. Hybrid
  • 12.3. On Premise

13. Brain Disease Modalities & Software Market, by Distribution Channel

  • 13.1. Direct
  • 13.2. Distributors
  • 13.3. Online Platforms

14. Brain Disease Modalities & Software Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Brain Disease Modalities & Software Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Brain Disease Modalities & Software Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Siemens Healthineers AG
    • 17.3.2. GE HealthCare Technologies Inc.
    • 17.3.3. Koninklijke Philips N.V.
    • 17.3.4. Canon Medical Systems Corporation
    • 17.3.5. Hitachi, Ltd.
    • 17.3.6. Brainlab AG
    • 17.3.7. Elekta AB (publ)
    • 17.3.8. Medtronic plc
    • 17.3.9. Stryker Corporation
    • 17.3.10. IBM Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY IMAGING MODALITY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY IMAGING MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SOFTWARE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SOFTWARE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DEPLOYMENT MODE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DEPLOYMENT MODE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. BRAIN DISEASE MODALITIES & SOFTWARE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. BRAIN DISEASE MODALITIES & SOFTWARE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BRAIN DISEASE MODALITIES & SOFTWARE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY IMAGING MODALITY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY IMAGING MODALITY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CONVENTIONAL CT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CONVENTIONAL CT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CONVENTIONAL CT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CONVENTIONAL CT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CONVENTIONAL CT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CONVENTIONAL CT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SPECTRAL CT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SPECTRAL CT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SPECTRAL CT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SPECTRAL CT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SPECTRAL CT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SPECTRAL CT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AMBULATORY EEG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AMBULATORY EEG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AMBULATORY EEG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AMBULATORY EEG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AMBULATORY EEG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AMBULATORY EEG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ROUTINE EEG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ROUTINE EEG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ROUTINE EEG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ROUTINE EEG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ROUTINE EEG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ROUTINE EEG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIFFUSION TENSOR IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIFFUSION TENSOR IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIFFUSION TENSOR IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIFFUSION TENSOR IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIFFUSION TENSOR IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIFFUSION TENSOR IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY FUNCTIONAL MRI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY FUNCTIONAL MRI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY FUNCTIONAL MRI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY FUNCTIONAL MRI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY FUNCTIONAL MRI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY FUNCTIONAL MRI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY STRUCTURAL MRI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY STRUCTURAL MRI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY STRUCTURAL MRI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY STRUCTURAL MRI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY STRUCTURAL MRI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY STRUCTURAL MRI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETOENCEPHALOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETOENCEPHALOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETOENCEPHALOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETOENCEPHALOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETOENCEPHALOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETOENCEPHALOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETOENCEPHALOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETOENCEPHALOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY EVOKED RESPONSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY EVOKED RESPONSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY EVOKED RESPONSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY EVOKED RESPONSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY EVOKED RESPONSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY EVOKED RESPONSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY RESTING STATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY RESTING STATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY RESTING STATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY RESTING STATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY RESTING STATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY RESTING STATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AMYLOID PET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AMYLOID PET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AMYLOID PET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AMYLOID PET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AMYLOID PET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AMYLOID PET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY FDG PET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY FDG PET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY FDG PET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY FDG PET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY FDG PET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY FDG PET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HIGH RESOLUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HIGH RESOLUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HIGH RESOLUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HIGH RESOLUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HIGH RESOLUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HIGH RESOLUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TRANSCRANIAL DOPPLER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TRANSCRANIAL DOPPLER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TRANSCRANIAL DOPPLER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TRANSCRANIAL DOPPLER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TRANSCRANIAL DOPPLER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TRANSCRANIAL DOPPLER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SOFTWARE TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SOFTWARE TYPE, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AI BASED SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AI BASED SOFTWARE, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AI BASED SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AI BASED SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AI BASED SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AI BASED SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AI BASED SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AI BASED SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DEEP LEARNING ALGORITHMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DEEP LEARNING ALGORITHMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DEEP LEARNING ALGORITHMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DEEP LEARNING ALGORITHMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DEEP LEARNING ALGORITHMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DEEP LEARNING ALGORITHMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MACHINE LEARNING ALGORITHMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MACHINE LEARNING ALGORITHMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MACHINE LEARNING ALGORITHMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MACHINE LEARNING ALGORITHMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MACHINE LEARNING ALGORITHMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MACHINE LEARNING ALGORITHMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CLINICAL DECISION SUPPORT SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CLINICAL DECISION SUPPORT SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CLINICAL DECISION SUPPORT SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CLINICAL DECISION SUPPORT SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CLINICAL DECISION SUPPORT SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CLINICAL DECISION SUPPORT SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIAGNOSTIC SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIAGNOSTIC SOFTWARE, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIAGNOSTIC SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIAGNOSTIC SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIAGNOSTIC SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIAGNOSTIC SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIAGNOSTIC SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIAGNOSTIC SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SEGMENTATION SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SEGMENTATION SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SEGMENTATION SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SEGMENTATION SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SEGMENTATION SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SEGMENTATION SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MONITORING SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MONITORING SOFTWARE, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MONITORING SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MONITORING SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MONITORING SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MONITORING SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MONITORING SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MONITORING SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEUROPHYSIOLOGICAL MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEUROPHYSIOLOGICAL MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEUROPHYSIOLOGICAL MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEUROPHYSIOLOGICAL MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEUROPHYSIOLOGICAL MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEUROPHYSIOLOGICAL MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY REMOTE PATIENT MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY REMOTE PATIENT MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY REMOTE PATIENT MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY REMOTE PATIENT MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY REMOTE PATIENT MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY REMOTE PATIENT MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TELEHEALTH PLATFORM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TELEHEALTH PLATFORM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TELEHEALTH PLATFORM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TELEHEALTH PLATFORM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TELEHEALTH PLATFORM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TELEHEALTH PLATFORM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY WORKFLOW MANAGEMENT SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY WORKFLOW MANAGEMENT SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY WORKFLOW MANAGEMENT SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY WORKFLOW MANAGEMENT SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY WORKFLOW MANAGEMENT SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY WORKFLOW MANAGEMENT SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY EPILEPSY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY EPILEPSY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY EPILEPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY EPILEPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY FOCAL ONSET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY FOCAL ONSET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY FOCAL ONSET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY FOCAL ONSET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY FOCAL ONSET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY FOCAL ONSET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY GENERALIZED ONSET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY GENERALIZED ONSET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY GENERALIZED ONSET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY GENERALIZED ONSET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY GENERALIZED ONSET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY GENERALIZED ONSET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY STROKE, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY STROKE, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY STROKE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY STROKE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY STROKE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY STROKE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY STROKE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY STROKE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HEMORRHAGIC STROKE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HEMORRHAGIC STROKE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HEMORRHAGIC STROKE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HEMORRHAGIC STROKE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HEMORRHAGIC STROKE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HEMORRHAGIC STROKE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY IS